QPPV.COM KNOWLEDGE ASSESSMENT

Monoclonal Antibodies: Classification and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Monoclonal Antibodies: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which example most clearly represents disease or treatment confounding in monoclonal-antibody surveillance?

An event occurs after exposure but is also common in the underlying disease and with a concomitant cytotoxic medicine A batch number is missing from a report An antibody has a humanised variable region The product is administered by the subcutaneous route

Question 2 of 10 A substantial increase in reports is observed after a monoclonal antibody enters a new indication. Which explanation should be evaluated before concluding that risk has increased?

Only a change in molecular structure Changes in exposure, population, background incidence, reporting behaviour and diagnostic recognition Only a change in product name The assumption that the new indication has the same baseline risk as the original indication

Question 3 of 10 A rise in adverse-event reports occurs shortly after a manufacturing-site change. What is the most appropriate initial approach?

Conclude that the site change caused the events Dismiss the pattern because causality cannot be established from spontaneous reports Integrate product identity, batch exposure, quality information, clinical phenotype and alternative explanations Assess only the number of reports without considering exposure

Question 4 of 10 Which statement best reflects the regulatory relationship between monoclonal-antibody pharmacovigilance and the EU GVP framework?

Monoclonal antibodies are governed by an entirely separate pharmacovigilance system General GVP processes apply, supplemented by antibody-specific scientific knowledge and controls Only immunogenicity guidance applies to monoclonal antibodies GVP processes apply only to small-molecule medicines

Question 5 of 10 What is the central objective of an effective monoclonal-antibody pharmacovigilance system?

To assign one generic adverse-event profile to the entire antibody class To maintain a defensible link between product, mechanism, exposure, clinical event, evidence, assessment and action To replace clinical development with spontaneous reporting To collect the largest possible number of data fields for every case

Question 6 of 10 Which combination provides the strongest basis for assessing the clinical relevance of immunogenicity?

Antibody origin category and product colour Anti-drug-antibody result alone Clinical chronology, antibody data, drug concentrations, treatment response and alternative explanations The number of patients enrolled in unrelated antibody trials

Question 7 of 10 What is the appropriate interpretation of a disproportional reporting pattern for a monoclonal antibody?

It is definitive proof of an increased incidence It is a starting point that requires clinical review and scientific validation It can be ignored if the event is biologically plausible It automatically establishes a class-wide risk

Question 8 of 10 Why can pharmacokinetic and pharmacodynamic information materially improve assessment of a suspected monoclonal-antibody adverse reaction?

It can help determine whether exposure and target engagement are compatible with the observed clinical event It eliminates the need to assess alternative causes It proves that every event occurring after dosing is treatment-related It is used only to confirm product naming

Question 9 of 10 Why must disease indication and concomitant therapy be preserved in aggregate safety analyses?

They determine the product's antibody origin They may influence baseline risk, exposure, confounding, treatment interactions and benefit–risk balance They are needed only for reimbursement purposes They eliminate the need for exposure denominators

Question 10 of 10 Why is antibody origin classification alone insufficient to predict the safety profile of a therapeutic monoclonal antibody?

Because all monoclonal antibodies have identical target biology regardless of sequence Because human sequence content is only one factor among product, treatment and patient-related determinants of safety Because antibody origin is relevant only to manufacturing and not to clinical effects Because fully human antibodies cannot induce immune responses

QPPV.com

Monoclonal Antibodies: Classification and Pharmacovigilance — Knowledge Assessment

Cookie Settings